Pleiotropic effects of ursodeoxycholic acid in non-alcoholic fatty liver disease and metabolic syndrome
- Authors: Pirogova I.Y.1, Yakovleva S.V.2, Neuimina T.V.2, Sinitsyn S.P.3, Chulkov V.S.3
-
Affiliations:
- South Ural State Medical University, Medical Center "Lotos"
- Medical Center "Lotos"
- South Ural State Medical University
- Issue: Vol 21, No 8 (2019)
- Pages: 65-70
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/96811
- DOI: https://doi.org/10.26442/20751753.2019.8.190365
- ID: 96811
Cite item
Full Text
Abstract
Aim. To study the effect of therapy on Ursosan that insulinoresistense and dyslipidemia, the stage of liver steatosis and liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) obesity and metabolic syndrome against the background of life style modification. Materials and methods. The study included 70 patients (36 men), mean age - median (Me)=45,6 with NAFLD on the background of overweight - Body Mass Index >30 kg/m2 (Me=32) with the syndrome of cytolysis >2 norms and/or liver fibrosis and liver steatosis ≥1 stage (FibroScan 502 TOUCH with ultrasonic sensor for fat patients and software CAP). The stigma of the lipid spectrum, insulinoresistense, inflammation. All patients were prescribed a diet combined with daily aerobic activity for 24 weeks, and patients of the main group (n=50) were additionally prescribed Ursosan in daily dose 15 mg/kg. Results. Both groups showed a decrease in Body Mass Index (-4.9% in the main group and -4.8% in the comparison group). Revealed a decrease in Me alanine transaminase by -24% (p<0.001) of group 1 and -11% (p<0.05) of group 2; a decrease in aspartate transaminase by -32% (p<0.001) and -13% (p<0.05), respectively; gamma-glutamyltransferase - -33% (p<0.001) and -22% (p<0.05), respectively; glycated hemoglobin -17% (p<0.05) and -10% (p>0.05), respectively; HOMA-index -15% (p<0.04) and -7% (p=0.1); total cholesterol -12% (p<0.05) and -5% (p=0.15); triglycerides -21% (p<0.05) and -9% (p>0.05); low-density lipoprotein - -21% (p<0.05) and -9% (p>0.05); high-density lipoprotein - +28% (p<0.05) and +5% (p=0.7); liver steatosis (DV/m2) - -26% (p<0.01) and -7% (p<0.05); liver fibrosis reduction by stage 1 (METAVIR) in 40% of patients of group 1. Conclusion. The use of Ursosan 15 mg/kg/day in patient with NAFLD, obesity and metabolic syndrome against the background of diet and exercise therapy can significantly reduce the stigma of inflammation, insulin resistance and dyslipidemia, liver steatosis compared with non-drug therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Irina Yu. Pirogova
South Ural State Medical University, Medical Center "Lotos"
Email: irina_pirogova@inbox.ru
D. Sci. (Med.), Prof. Chelyabinsk, Russia
Sofia V. Yakovleva
Medical Center "Lotos"
Email: yakovlevas7479@yandex.ru
Head of the Department of Therapy Chelyabinsk, Russia
Tatyana V. Neuimina
Medical Center "Lotos"doctor-gastroenterologist Chelyabinsk, Russia
Sergey P. Sinitsyn
South Ural State Medical University
Email: sinitsinsp@lenta.ru
D. Sci. (Med.), Prof. Chelyabinsk, Russia
Vasily S. Chulkov
South Ural State Medical UniversityD. Sci. (Med.), Prof. Chelyabinsk, Russia
References
- http://www.who.int/mediacentre/factsheets/fs311/ru/
- Ervin R.B. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; 13: 1-7.
- Demir M, Lang S, Steffen H.M. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015; 16 (10): 541-57. doi: 10.1111/1751-2980.12291
- Структура заболеваний печени мегаполиса по результатам акции «Проверь свою печень». Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; XXVI (1): 59. @@Struktura zabolevanii pecheni megapolisa po rezul'tatam aktsii "Prover' svoiu pechen''. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; XXVI (1): 59 (in Russian)
- Masarone M, Federico A, Abenavoli L et al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9 (3): 126-33. doi: 10.2174/1574887109666141216111143
- Bhala N, Jouness R.I, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19 (29): 5169-76. doi: 10.2174/13816128113199990336
- Adams L.A, Feldstein A.E. Nonalcoholic steatohepatitis: risk factors and diagnosis. Exp Rev Gastroenterol Hepatol 2010; 4 (5): 623-5.
- Feldstein A.E, Ganbay A, Angulo P. Hepatosite apoptosisand fas expressionare prominent features of human nonalcogolic steatogepatitis. Gastroenterology 2003; 125 (2): 437-43.
- Маев И.В., Кучерявый Ю.А., Морозов Ю.А. Влияние урсодезоксихолевой кислоты в качестве монотерарапии и в комбинации с лактулозой на биохимические показатели крови у больных неалкогольным стеатогепатитом. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (1): 37-51 @@Maev I.V., Kucheriavyi Iu.A., Morozov Iu.A. Vliianie ursodezoksikholevoi kisloty v kachestve monoterarapii i v kombinatsii s laktulozoi na biokhimicheskie pokazateli krovi u bol'nykh nealkogol'nym steatogepatitom. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (1): 37-51 (in Russian)
- Shi K.Q et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29 (6): 1149-58.
- Сlassens M, Van Baak Monsheimer S, Saris W.H.M. The effect of low-fats high - protein or high carbohydrate ad libitum diet on weight loss maintenance and metabolic risk factors. Int J Obes 2009; 33 (3): 296-304.
- Noakes M, Kleogh J.B, Foster P.R, Clifton P.M. Effect of energy restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional station, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005; 81 (6): 1298-306.
- Frari J.M, Bjerry K.P, Glinboard D, Ravn P. The effect of dietary carbohydrates in women with polycystic ovary syndrome. Minerva Endjcrinol 2014. [Epub ahead of print.]
- Ivashkin V, Drapkina O. The prevalence of nonalcogolic fatty liver desease in Russion Federation. Gut 2009; 58: 1207
Supplementary files
